Finoriq research workspace
Janux Therapeutics, Inc. (JANX) Company Overview
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on. Review JANX filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
- Company
- Janux Therapeutics, Inc. (JANX)
- Ticker
- JANX
- Market Cap
- $985.2M
- Latest Price
- $16.16
- Industry
- Biotech & Pharma
Janux Therapeutics, Inc. (JANX) Current Valuation Metrics
Static valuation preview for Janux Therapeutics, Inc. (JANX). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 102x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -11.1% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.1% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 1.07x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.